Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

The Revolution in Cancer Treatment

The Revolution in Cancer Treatment

One of the most frequently asked questions and most common thoughts in society is: “A treatment for cancer has actually been found, but it is being hidden. We are being given old treatments. Pharmaceutical companies keep innovations away from society and cancer patients so they can sell the drugs or technology they already have.” Is this idea correct? Have there really been important changes in cancer treatment in recent years?

In fact, we have only just begun to learn about cancer. We could even say that we have only just begun to utter the word cancer. Looking at it in this context, or comparing cancer with the better-known infectious diseases, helps us understand this situation much better. Infectious diseases are a group of diseases that society has known about for centuries and continues to learn about every day. For example, today there is no complete treatment for a life-threatening infectious disease such as AIDS. Or, although we know that there is no treatment for a new type of influenza emerging each year, we do not say that infectious diseases have no treatment. Looking over the years, we have seen that infectious diseases actually have hundreds of subgroups and consist of more than thousands of disease groups. The world has now solved some of these diseases. For example, thanks to vaccines developed against infectious diseases such as chickenpox and polio, we are now protected against them. However, we also know that certain newly identified influenza diseases cost a group of people their lives. Yet we do not lose hope in this process. We know that solutions will be produced over time and vaccines will be developed against them too. What distinguishes infectious diseases from cancer here is that infectious diseases have been known for centuries, while the scientific community began learning about cancer in the past 50 years. In the past 20 years, there have been developments that truly change people’s lives. Looking at the period before 2000, the life of one out of 3 cancer patients was saved, whereas today two out of 3 cancer patients regain their health. This is a major figure.. Moreover, going back only 10 years, leukemia (blood cancer) was among the deadliest disease groups, whereas today the 5-year recovery rate from leukemia has reached 60-70%. We know that a large proportion of this disease is treated through the development and frequent use of stem cell transplantation, made possible by obtaining stem cells from suitable donors or from the individual. In other words, we can say that stem cells emerged as a revolution in blood cancers or lymph node cancers. They changed people’s lives and came to free a large proportion of them from the disease.

Turning to other cancer types, there have also been revolutionary changes in the past 20 years in organ cancers, which we call organ solid tumors. Gastrointestinal stromal tumors are one of the earliest examples: before 2000, their response rate to the chemotherapy we used was 8%, meaning that when we gave chemotherapy to 100 patients, only 8 responded, whereas today we can obtain response rates exceeding almost 90%. Even in disease that has progressed over many years or spread throughout the body, we can achieve very positive results with oral treatments. Glivek can be given as an example of these treatments. Later, multiple drugs emerged in this group, providing solutions even when Glivek was insufficient. We call this group targeted drugs. Targeted drugs, in other words smart drugs, precisely identify the cancer’s growth mechanism and directly block either the factors triggering it or the mechanism itself, preventing cancerous transformation or eliminating a cell that has become cancerous; they have begun to be used in many fields. While they work alone in certain cancer types, their use together with chemotherapy has created major advantages in others. Some are smart drugs that bind directly to certain receptors on the cell surface; others capture the stimulating substances that bind to these receptors and activate cellular growth pathways, eliminating their effects. A group of drugs we call small molecules enters the cell directly and blocks the mechanisms that carry or transmit the growth signal from the cell nucleus stimulating the tumor within the cell. Today these drugs also make life-changing contributions in many cancer types.

We must not forget that, although pharmaceutical companies have brought enormous changes to our lives in recent years, they have also experienced great disappointments. Today, many companies—almost more than 250—trying to develop promising drugs targeting growth pathways have disappeared because of enormous costs. An unsuccessful result caused them to lose everything. Thus, the process of discovering and developing a drug and making it available for a disease can cost a company or group of companies billions of dollars. Under such circumstances, a drug based on years, effort and substantial financial resources cannot be hidden from people in today’s conditions. As we stated at the beginning of this article, it must be remembered that cancer consists of multiple diseases, like infectious diseases, and almost all have different mechanisms of development. Naturally, their treatment mechanisms differ too. Today there are more than 150 defined cancer types. Cancers also behave differently according to their stage. If we examine each cancer type in 4 stages, considering 150 subgroups, we can suddenly face thousands of diseases. Sometimes we can examine even a single disease under 10-15 subheadings. When we multiply cancers by these figures, a series of thousands of diseases suddenly appears before us. For this reason, we encounter differences in the treatment, diagnosis and course of almost all of them.

However, the fact that all of these are called cancer may be the most important reason for this misconception. In my opinion, cancer began to be recognized in developed countries after the 1960s, with the recognition and development of individual rights and freedoms. However, when it comes to countries in Eastern Europe and the East, be assured that these are very new concepts. This new terminology has only recently reached the public. We have only just begun to understand this series of multiple diseases, their mechanisms of development, and the fact that treatment strategies and developed methods will differ. Have these smart drugs brought substantial developments in cancer treatment? Yes, they have. But these drugs have also remained insufficient in many cancer types. Nevertheless, studies conducted in the past 20 years now contribute to survival in many cancer types, including advanced renal cell cancer, liver cancer, stomach cancer, breast cancer, lung cancer and brain cancer. Are these sufficient? Of course not. Science has begun to turn in a very different direction, as it has become apparent that treating cancer does not involve only the cancer cell. Identifying certain changes in the body’s defense system—that is, detecting defects in the defense system we call the immune system and developing treatments for them—in other words, drugs developed for defense cells and certain vaccines, has begun to take cancer treatment to another dimension. Adding combinations of these to the treatments we already use has been a new light. We have now begun to see and hear the signs of new footsteps in oncology. I believe that within a period such as 10 years, drugs regulating the immune system will bring a new breath and a light to oncology following targeted drugs.

Are all the developments in cancer treatment present in our lives through drugs? No, of course these developments have not been limited to drugs. There have also been incredible advances in surgical techniques. We no longer have the very extensive operations of the past. Instead, methods have developed that are more humane, preserve the body better, cause fewer adverse effects and allow patients to recover sooner. For example, whereas almost 80% of breast cancer patients previously lost their breast, today only approximately 10-20% of these patients lose their breast. Particularly in advanced centers and clinics where multiple physicians specialize in their fields and work in a multidisciplinary manner, breast loss has been reduced to almost negligible levels. Robotic methods and closed laparoscopic methods have become highly advanced for intra-abdominal cancers, head and neck cancers and lung cancers. With the participation of plastic surgeons in cancer surgery, more aggressive operations have become easier to perform, with less disruption of the patient’s appearance. As can be seen, these developments observed in surgery over the past 20 years are actually revolutionary.

Imaging is another field where, in my opinion, perhaps the most important revolutionary changes have occurred, facilitating cancer management and enabling us to guide it correctly. The more accurately you image a cancer and determine its spread, the more the decisions you make for that patient will change accordingly. Imaging methods we call molecular imaging, which began particularly with PET Tomography, are now very popular. However, changes in technology alone are not enough. Physicians who use it well are also needed. Having a good device is not sufficient. Imaging specialists who are experts in their field, committed to oncology and have continued developing in this direction change not only the outlook of the medical oncologist, radiation oncologist or surgeon with whom they work in a multidisciplinary team, but also the patient’s life. For example, imaging in prostate cancer has reached a very advanced level. Looking back 5 years, we determined prostate cancer distribution with very simple methods; today, PET Tomography directed at the contents of the prostate cell itself, which we call prostate-specific membrane antigen, enables a much more comprehensive assessment of prostate cancer. Neuroendocrine tumors are a group of tumors that can originate anywhere in the body, particularly developing from hormone-secreting cells. Imaging of these tumors developing from hormone-mediated cells has reached a very different dimension. Using a substance called Gallium 68, tumor cells can be assessed much more comprehensively, and their presence can be detected almost at the cellular level. In addition, smart-drug treatments directed at the identified tumor cell and radiation treatments directed directly at the cell can be administered. As can be seen, changes emerging in nuclear medicine in both imaging and molecular treatment are revolutionary. They have added life to life.

The beta-radiation-emitting particles called samarium or strontium previously used in prostate cancer did not prolong life. Yes, when we used them for years in prostate cancer patients, they reduced bone pain. However, a drug called paradin, which emits alpha radiation and which I believe will enter our country very soon, can irradiate only the involved areas in bone through a substance administered intravenously. It also plays an effective role in reducing the patient’s pain and makes extremely substantial contributions to survival. This is another example of molecular treatment and a revolutionary development in nuclear medicine. We are certain that this and similar applications will become available for use in many cancer types in the coming period as cancer cells become better understood.

Interventional radiological methods are rapidly developing methods that enable a tumor to be destroyed in its location without the need for surgery. Radiofrequency ablation, meaning heat treatment of the tumor using radiofrequency; cryoablation, destruction of the tumor by freezing; nanoknife, the name given to tumor destruction using high electrical voltages; and HIFU, performed using high-frequency ultrasound waves, have broken new ground in many cancer types today. In addition, treatments administered directly through an artery, namely intra-arterial treatments, and the ability to obtain 3-dimensional tomography images during angiography, particularly with the development of DyneCT, have enabled identification of the vessel truly feeding the tumor. This device, which entered our lives in the past few years, has enabled us to find the vessels directly feeding the tumor and deliver concentrated amounts of chemotherapy.

Radiotherapy has shown incredible movement over the past 50 years. Its development over the past 20 years has been truly revolutionary. Advances in radiotherapy have enabled enormous successes today through devices delivering radiation treatment directly targeting the tumor while preserving healthy tissue. The tumor is targeted directly, and healthy tissue is protected to the greatest possible extent. The more healthy tissue you can protect, naturally the more radiation you can deliver to the tumor. Thanks to these new developments, radiotherapy has now become a ray of hope in many inoperable cancer types. Head and neck cancer, pancreatic cancer, bile duct cancer, cervical cancer and uterine cancer are examples, and this list can be expanded.

One of the most important revolutionary points is that the perspective on the cancer patient has now changed. Quality of life has taken precedence over almost everything. The harm you may cause when treating a patient is now measured alongside the benefit you will provide. Alternative medicine methods that improve quality of life, which we call evidence-based complementary methods, have come to be used much better. Reducing the patient’s pain, eliminating anxiety and tension, resolving insomnia and sexual problems, and minimizing drug adverse effects—all collectively expressed as quality of life—have taken patients to a different place. They have gained the trust of the entire oncology community and enabled patients to hold on to life. Looking from within the difficult situation we find ourselves in, we may genuinely feel that there is no treatment for cancer and that no progress is being made. However, as you can see, there are actually numerous revolutionary developments in oncology.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

The Revolution in Cancer Treatment

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy